S&P 500   4,225.46 (-1.47%)
DOW   32,973.01 (-1.38%)
QQQ   353.92 (-2.03%)
AAPL   172.13 (-0.93%)
MSFT   312.28 (-2.96%)
META   300.07 (-2.20%)
GOOGL   132.09 (-1.55%)
AMZN   124.63 (-3.73%)
TSLA   246.26 (-2.12%)
NVDA   435.02 (-2.86%)
NIO   8.67 (-1.37%)
BABA   84.47 (-2.38%)
AMD   99.60 (-3.55%)
T   14.80 (+0.89%)
F   12.10 (-1.71%)
MU   67.62 (-0.50%)
CGC   0.68 (-7.41%)
GE   107.67 (-1.03%)
DIS   79.66 (-2.46%)
AMC   7.98 (-2.09%)
PFE   34.01 (+0.21%)
PYPL   57.29 (-2.17%)
NFLX   375.12 (-1.37%)
S&P 500   4,225.46 (-1.47%)
DOW   32,973.01 (-1.38%)
QQQ   353.92 (-2.03%)
AAPL   172.13 (-0.93%)
MSFT   312.28 (-2.96%)
META   300.07 (-2.20%)
GOOGL   132.09 (-1.55%)
AMZN   124.63 (-3.73%)
TSLA   246.26 (-2.12%)
NVDA   435.02 (-2.86%)
NIO   8.67 (-1.37%)
BABA   84.47 (-2.38%)
AMD   99.60 (-3.55%)
T   14.80 (+0.89%)
F   12.10 (-1.71%)
MU   67.62 (-0.50%)
CGC   0.68 (-7.41%)
GE   107.67 (-1.03%)
DIS   79.66 (-2.46%)
AMC   7.98 (-2.09%)
PFE   34.01 (+0.21%)
PYPL   57.29 (-2.17%)
NFLX   375.12 (-1.37%)
S&P 500   4,225.46 (-1.47%)
DOW   32,973.01 (-1.38%)
QQQ   353.92 (-2.03%)
AAPL   172.13 (-0.93%)
MSFT   312.28 (-2.96%)
META   300.07 (-2.20%)
GOOGL   132.09 (-1.55%)
AMZN   124.63 (-3.73%)
TSLA   246.26 (-2.12%)
NVDA   435.02 (-2.86%)
NIO   8.67 (-1.37%)
BABA   84.47 (-2.38%)
AMD   99.60 (-3.55%)
T   14.80 (+0.89%)
F   12.10 (-1.71%)
MU   67.62 (-0.50%)
CGC   0.68 (-7.41%)
GE   107.67 (-1.03%)
DIS   79.66 (-2.46%)
AMC   7.98 (-2.09%)
PFE   34.01 (+0.21%)
PYPL   57.29 (-2.17%)
NFLX   375.12 (-1.37%)
S&P 500   4,225.46 (-1.47%)
DOW   32,973.01 (-1.38%)
QQQ   353.92 (-2.03%)
AAPL   172.13 (-0.93%)
MSFT   312.28 (-2.96%)
META   300.07 (-2.20%)
GOOGL   132.09 (-1.55%)
AMZN   124.63 (-3.73%)
TSLA   246.26 (-2.12%)
NVDA   435.02 (-2.86%)
NIO   8.67 (-1.37%)
BABA   84.47 (-2.38%)
AMD   99.60 (-3.55%)
T   14.80 (+0.89%)
F   12.10 (-1.71%)
MU   67.62 (-0.50%)
CGC   0.68 (-7.41%)
GE   107.67 (-1.03%)
DIS   79.66 (-2.46%)
AMC   7.98 (-2.09%)
PFE   34.01 (+0.21%)
PYPL   57.29 (-2.17%)
NFLX   375.12 (-1.37%)
NASDAQ:APLM

Apollomics (APLM) Stock Forecast, Price & News

$3.55
-0.05 (-1.39%)
(As of 03:50 PM ET)
Compare
Today's Range
$3.50
$3.60
50-Day Range
$3.60
$5.74
52-Week Range
$3.48
$49.00
Volume
2,121 shs
Average Volume
87,638 shs
Market Capitalization
$308.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Apollomics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Apollomics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.62) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars

Medical Sector

934th out of 976 stocks

Pharmaceutical Preparations Industry

429th out of 447 stocks


APLM stock logo

About Apollomics (NASDAQ:APLM) Stock

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

APLM Price History

APLM Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
APLM - Apollomics, Inc.
Apollomics (NASDAQ: APLM)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
See More Headlines
Receive APLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

APLM Company Calendar

Today
10/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLM
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.45 million
Book Value
($33.37) per share

Miscellaneous

Free Float
N/A
Market Cap
$312.48 million
Optionable
Not Optionable
Beta
1.11
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Guo-Liang Yu Ph.D. (Age 60)
    Co-Founder, CEO & Exec. Chairman
  • Dr. Sanjeev Redkar MBA (Age 54)
    Ph.D., Co-Founder, Pres, CFO & Exec. Director
  • Dr. Lijuan Jane Wang Ph.D. (Age 59)
    Chief Scientific Officer & GM of China
  • Ms. Brianna MacDonald J.D.
    Sr. VP & Gen. Counsel
  • Dr. Kin-Hung Yu M.D. (Age 61)
    Chief Medical Officer
  • Dr. Chinglin Lai Ph.D.
    Sr. VP of Biostatistics & Data Management













APLM Stock - Frequently Asked Questions

Should I buy or sell Apollomics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APLM shares.
View APLM analyst ratings
or view top-rated stocks.

How have APLM shares performed in 2023?

Apollomics' stock was trading at $24.20 at the start of the year. Since then, APLM shares have decreased by 85.1% and is now trading at $3.60.
View the best growth stocks for 2023 here
.

Are investors shorting Apollomics?

Apollomics saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 3,300 shares, a drop of 19.5% from the August 31st total of 4,100 shares. Based on an average daily volume of 17,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's stock are sold short.
View Apollomics' Short Interest
.

What ETF holds Apollomics' stock ?

Range Cancer Therapeutics ETF holds 26,270 shares of APLM stock, representing 1.45% of its portfolio.

What is Apollomics' stock symbol?

Apollomics trades on the NASDAQ under the ticker symbol "APLM."

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollomics' stock price today?

One share of APLM stock can currently be purchased for approximately $3.60.

How much money does Apollomics make?

Apollomics (NASDAQ:APLM) has a market capitalization of $312.48 million and generates $1.45 million in revenue each year.

How can I contact Apollomics?

Apollomics' mailing address is 5/F-4 NO. 89 SONGREN ROAD XINYI DISTRICT, TAIPEI CITY F5, 11073. The official website for the company is www.apollomicsinc.com. The company can be reached via phone at 886-2-7713-7952.

This page (NASDAQ:APLM) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -